WO1989009049A1 - Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration - Google Patents
Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration Download PDFInfo
- Publication number
- WO1989009049A1 WO1989009049A1 PCT/US1989/001400 US8901400W WO8909049A1 WO 1989009049 A1 WO1989009049 A1 WO 1989009049A1 US 8901400 W US8901400 W US 8901400W WO 8909049 A1 WO8909049 A1 WO 8909049A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- injectable
- per day
- magnetized
- times per
- Prior art date
Links
- 230000001632 homeopathic effect Effects 0.000 title claims abstract description 169
- 238000000034 method Methods 0.000 title claims abstract description 84
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 106
- 238000001467 acupuncture Methods 0.000 claims abstract description 92
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 239000000126 substance Substances 0.000 claims abstract description 35
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 27
- 241000282414 Homo sapiens Species 0.000 claims abstract description 16
- 239000012676 herbal extract Substances 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 4
- 230000004044 response Effects 0.000 claims abstract 3
- 239000000243 solution Substances 0.000 claims description 37
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 208000024891 symptom Diseases 0.000 claims description 25
- 239000006187 pill Substances 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- 235000008216 herbs Nutrition 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 208000014674 injury Diseases 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 230000003054 hormonal effect Effects 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 241001673966 Magnolia officinalis Species 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 235000019504 cigarettes Nutrition 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000000779 smoke Substances 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 230000004907 flux Effects 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 230000008736 traumatic injury Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 244000118350 Andrographis paniculata Species 0.000 claims description 2
- 241000382455 Angelica sinensis Species 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 241001061264 Astragalus Species 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 244000284152 Carapichea ipecacuanha Species 0.000 claims description 2
- 235000004032 Centella asiatica Nutrition 0.000 claims description 2
- 244000146462 Centella asiatica Species 0.000 claims description 2
- 240000005250 Chrysanthemum indicum Species 0.000 claims description 2
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims description 2
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 2
- 241000218158 Clematis Species 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 244000055664 Dichroa febrifuga Species 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 241001465251 Ephedra sinica Species 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 claims description 2
- 241001071795 Gentiana Species 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 235000003470 Ilex asprella Nutrition 0.000 claims description 2
- 241001100541 Ilex asprella Species 0.000 claims description 2
- 235000017617 Lonicera japonica Nutrition 0.000 claims description 2
- 244000167230 Lonicera japonica Species 0.000 claims description 2
- 235000011779 Menyanthes trifoliata Nutrition 0.000 claims description 2
- 240000008821 Menyanthes trifoliata Species 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 240000001382 Ornithogalum umbellatum Species 0.000 claims description 2
- 235000016547 Ornithogalum umbellatum Nutrition 0.000 claims description 2
- 241000120647 Osbeckia Species 0.000 claims description 2
- 241000123887 Pulsatilla chinensis Species 0.000 claims description 2
- 244000294611 Punica granatum Species 0.000 claims description 2
- 235000014360 Punica granatum Nutrition 0.000 claims description 2
- 244000097577 Rhus javanica Species 0.000 claims description 2
- 235000010889 Rhus javanica Nutrition 0.000 claims description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 2
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 244000248021 Vitex negundo Species 0.000 claims description 2
- 235000010363 Vitex negundo Nutrition 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 235000019788 craving Nutrition 0.000 claims description 2
- 206010016766 flatulence Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 244000000053 intestinal parasite Species 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 210000004233 talus Anatomy 0.000 claims description 2
- 235000019505 tobacco product Nutrition 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims 14
- 238000012423 maintenance Methods 0.000 claims 13
- 239000002904 solvent Substances 0.000 claims 4
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 235000007070 Angelica archangelica Nutrition 0.000 claims 1
- 241000404028 Anthemis Species 0.000 claims 1
- 241000208306 Apium Species 0.000 claims 1
- 241000049464 Artemisia apiacea Species 0.000 claims 1
- 235000011570 Artemisia caruifolia var apiacea Nutrition 0.000 claims 1
- 241000207199 Citrus Species 0.000 claims 1
- 235000002873 Gentiana lutea Nutrition 0.000 claims 1
- 240000003409 Gentiana lutea Species 0.000 claims 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 1
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 1
- 235000005717 Grindelia squarrosa Nutrition 0.000 claims 1
- 244000259229 Grindelia squarrosa Species 0.000 claims 1
- 241001530884 Gynura segetum Species 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- 241000245240 Lonicera Species 0.000 claims 1
- 235000005321 Marrubium vulgare Nutrition 0.000 claims 1
- 244000137850 Marrubium vulgare Species 0.000 claims 1
- 235000010624 Medicago sativa Nutrition 0.000 claims 1
- 240000004658 Medicago sativa Species 0.000 claims 1
- 241000378467 Melaleuca Species 0.000 claims 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 241001523348 Picrasma Species 0.000 claims 1
- 241000734672 Polygala senega Species 0.000 claims 1
- 241000219093 Rhamnus Species 0.000 claims 1
- 241000233910 Serenoa Species 0.000 claims 1
- 235000008981 Smilax officinalis Nutrition 0.000 claims 1
- 240000002493 Smilax officinalis Species 0.000 claims 1
- 241000257673 Strobilanthes cusia Species 0.000 claims 1
- 240000001949 Taraxacum officinale Species 0.000 claims 1
- 235000006754 Taraxacum officinale Nutrition 0.000 claims 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims 1
- 235000020971 citrus fruits Nutrition 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 238000011418 maintenance treatment Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 239000009685 tusanqi Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 93
- 230000000699 topical effect Effects 0.000 abstract description 12
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 229940098465 tincture Drugs 0.000 description 36
- 238000009472 formulation Methods 0.000 description 24
- 239000004222 ferrous gluconate Substances 0.000 description 22
- 229960001645 ferrous gluconate Drugs 0.000 description 22
- 235000013924 ferrous gluconate Nutrition 0.000 description 22
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 22
- 239000006186 oral dosage form Substances 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 14
- 239000012895 dilution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000009025 Endorphins Human genes 0.000 description 3
- 108010049140 Endorphins Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000617 arm Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 235000011475 lollipops Nutrition 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000030710 Cynura Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000556074 Grindelia camporum Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000100289 Lonicera confusa Species 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000004659 Picrasma quassioides Species 0.000 description 1
- 235000010913 Picrasma quassioides Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 241000985696 Tecoma Species 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- This invention relates to homeopathic medicament? and methods for the treatment of illness and injury in human being ⁇ u ⁇ ir ⁇ such homeopathic medicaments.
- the invention relates to homeopathic methods of treatment of conditions including illnesses, pathogenic diseases, allergies, chemical and hormonal imbalances, addictive chemical dependencies, and physical injuries to the human body.
- the methods of treatment include oral, topical, auricular and injectable forms of homeopathic formulations which are magnetically treated or influenced during administeration to a patient through specific acupuncture points.
- Homeopathy is an ancient healing art and forms a vital part of medical therapy.
- the practice of homeopathy is widespread, particularly in eastern cultures and many European countries.
- Homeopathic medicine teaches the use cf natural based remedies and, as such, provides an alternative to traditional allopathic medicine which relies heavily on the use of petrochemical based pharmaceuticals.
- Homeopathic remedies use pharmaceutical preparations based on the use of herbs or herbal extracts.
- Homeoparhic remedies function in a totally different manner than chemical-based pharmaceuticals in that _ ⁇ _ they do not require administering high concentration? of active ingredient to produce the desired results.
- Traditional allopathic pharmaceuticals can be thought of as working quantitatively, that is, the results achieved are generally proportional to the potency and frequency of the dosage administered.
- homeopathic pharmaceuticals can be thought of as working- qualitatively in that even the minutest quantities of their active ingredients produce a therapeutic effect by inducing natural body mechanisms to return to their proper level of activity characteristic of a healthful or uninjured state.
- Homeopathic remedies function by inducing natural body mechanisms and processes to return to their optimum healthful level of operation; that is, their natural biological "set points". Through our modern understanding of genetics each bodily member and process is seen as the result of codes programmed into each individual cell.
- Homeopathic medicine seeks to utilize natural substances, particularly herbs, to naturally and gently induce the body to restore its equilibri- um, that is, for all function and processes to return to their set points.
- Homeopathic medicine looks upon illness and disease as being a state of disequilibrium from the body's optional set points.
- a fundamental precept of homeopathic medicine is that a small force or stimulating agent can produce disproportionally greater results, if optimally and effectively applied.
- homeopathic medicaments are relatively inexpensive as compared to traditional chemical-based pharmaceuticals.
- Another fundamental precept in the formulation of homeopathic pharmaceuticals is that repetitive dilution from an original concentrate does not diminish efficacy of the formulation.
- Acupuncture involves the relief of symptoms and the cure of illness and injury by the controlled stimulation of points on the human body which regulate or interact with the functioning of specific organs or bodily members to which the acupuncture points are related.
- the pain cycle can be broken and the natural healing process induced.
- Stimulation through acupunc- ture which typically involves the insertion of small needles into the acupuncture points on the body, causes a release of endorphins which block pain sensed over the neurological pathways and enable other natural healing mechanisms in the body to restore a condition of homeopathic equilibrium to the body by killing invasive pathogens, restoring chemical or hormonal imbalance . or fostering the mending of physically injured tissues, muscles and/or bones.
- specific points on the human body have been determined which regulate the functioning of all bodily members and processes.
- the appropriate points for stimulation for any given condition are known to skilled practitioners in the art.
- One particular acupuncture treatment system developed in Japan by Dr. Yo ⁇ hic Manaka is based on a conception of the human body as encompassing two basic systems, an energetic system and an informational system.
- the energetic system utilizes the greater portion of energy in the body.
- the informational system controls the energetic system and responds to both external and internal stimuli.
- Acupuncture is viewed, as a therapeutic modality which interacts with and regulates the body's informational system.
- the human body's susceptibility to magnetic fields is due in large part to the electrolytic properties of many of the chemical constituents of the body. All electrolytic substances are capable of conducting an electric current and wherever an electric current is flowing, a magnetic field is created. The greater the electrolytic properties of the substance, the greater is its conductivity and therefore the greater the resulting magnetic field created during current flow.
- the body generates a magnetic field of its own due " partly to the presence of iron ⁇ carrying charged particles flowing in the blood stream.
- Other electrolytic substances in the body such as potassium and sodium, in ionic form, are present in substantial amounts and contribute to the body's overall bioelectric/biomagnetic field.
- blood cells are readily polarized when placed in a magnetic field due to the high iron concentration in the blood. Under certain conditions, magnetic fields alter the orientation of blood cells and induce changes in the biological reactions in which they participate, thereby modifying the probability of chemical bond formation.
- Human blood is very slightly alkaline with respect to body cells which are more acidic. Magnetic fields can be used to induce reactions which restore the pH of the blood.
- Therapeutic magnetic energy fields also produce a stimulating component which in the case of traumatic physical injury dilates blood vessels and increases blood circulation, disperses fluid build-up due to inflammation, and strengthens and promotes the healing of damaged tissue.
- pulsed magnetic energy has been observed to cause transcutaneous electrical neural stimulation and contributes to the reduction of chronic pain by causing the release of natural pain relieving substances at the spinal cord level and by causing the release of endorphins and ACTH at the pituitary gland level.
- a primary object of the present in ⁇ vention is to disclose a new modality of medical therapy which utilizes aspects of homeopathic pharmaceutical therapy, acupuncture therapy and biomagnetic therapy, in combination.
- a further object of the invention is to devise a full range of modes of administration of magnetically induced homeopathic remedies, including topical, injectable, auricular and oral forms.
- a further object of the invention is to provide particular homeopathic pharmaceutical formulations for the treatment of specific illnesses, physical injuries and other chemical and hormonal disequilibrium conditions of the human body with precisely determined acupuncture sites to which the homeopathic pharmaceutical remedies are to be applied in the treatment of each specific condition.
- a further object of the invention is to provide appropriate means for inducing the biomagnetic field in the homeopathic pharmaceutical remedy for each form of adminis ⁇ tration.
- the present invention is directed to a method of treatment of human illness and injury by administering to the patient homeopathic medicaments through selected acupuncture points stimulated by a controlled magnetic field.
- a very " broad spectrum of human illnesses can be effectively treated by homeopathic medicaments of the instant invention through selection of the appropriate homeopathic remedy, preparation of a mixture of the homeopathic remedy and a magnetically permeable component and magnetization of the resulting mixture, during administration to the patient through specific acupuncture sites.
- Various embodiments of the invention include administering therapeutic amounts of the magnetic mixture in oral, injectable, topical and auricular forms. Further, depending upon the condition being treated the dosage and frequency of administration will vary. In a particularly preferred embodiment the patient is administered with a regimen of both oral and injectable dosages.
- Figures 1A and IE show two preferred embodiments of oral delivery vehicles for the administration of homeopathic medicaments
- Figures 2A and 2B show embodiments for the topical administration of a homeopathic medicament
- Figure 3 shows a preferred embodiment for imparting a magnetic field to the injectable form homeopathic medicaments
- the homeopathic medicaments of the present invention when administered through specific acupuncture sites have demonstrated remarkable efficacy in the treatment of a wide range of afflictions, many of which have no known cure in the realm of allopathic medicine.
- Effective delivery systems for these homeopathic formulations have been devised including topical, injectable, auricular and oral forms.
- the homeopathic medicament administered in whatever form is selected, must first be carefully mixed with an. effective amount of a magnetically permeable ingredient.
- a magnetically permeable ingredient such as sodium sulfate, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium EDTA, sodium sulfate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium
- One delivery system used is by injection.
- the formulation dosage and duration of treatment for the injectible medicaments is described in detail in the formulation examples which follow. Since it has been observed that injecting homeopathic medicaments demonstrate unexpected and significantly enhanced efficacy when a unipolar magnetic charge is imparted to the medicament during administration or injection into an acupuncture point, a device has been developed to enable the administering physician to suitably charge the medicament.
- One such device is shown in Figure 3. This device consists of a housing 10 containing an electromagnetic coil 12 positioned to impart a controlled magnetic charge to plate 14.
- a syringe or hypodermic needle 16 used to inject the homeopathic medicament can be positioned in housing 10 such that the point of the needle or syringe is in close proximity to plate 14 as shown in Figure 3.
- Topical Another alternative delivery system used is the topical.
- the topical patch 20 is made cf a porous material such a ⁇ sintered metal capable of absorbing a therapeutic amount of homeopathic medicament.
- the patch 20 has an extended opening therethrough in which is tightly fitted a metal rod or core 22 which can readily accept and retain a magnetic charge. Suitable materials include iron and nickel.
- the patch 20 can then be impregnated with a therapeutic amount of desired homeopathic medicament.
- a unipolar magnetic charge is then imparted to the metallic core 22 of patch 20 which is then affixed to a suitable acupuncture point.
- One method for affixing the topical patch to the acupuncture point is to hold it in place with adhesive bandage, surgical tape or the like.
- the magnetically influenced homeopathic medicament can be placed in a band which can be comfortably strapped around the member at the desired location.
- the homeopathic pharmaceutical formulation can be magnetized _in situ by placing a permanent magnet or ether source of magnetic flux on top of the portion of the homeopathic mixture to be agnet- ically activated.
- FIG. 2B Still another form of a topical for administering homeopathic medicaments is a pellet or "button" as illustrated in Figure 2B.
- the button 30 can be stamped out under pressure in a process generally known as the sintered metal process.
- a 50/50 powdered mixture of Ni (nickel) and Fe (iron) is fed into a press mold. This composition inhibits corrosion and readily accepts and holds a magnetic charge. Since the finished pellet or button is porous it can easily be impregnated like a sponge with a therapeutic homeopathic tincture.
- the button is then formed with pressure to the desired shape.
- buttons 30 effectively increases the overall therapeutic effect cf the topical by providing direct physical stimulation of the acupuncture point.
- the smooth domed top of button 30 is desirable as being less obtrusive on the surface cf the skin.
- the button 30 is formed and impregnated with medicament, it is magnetically charge so that the desired polarity is imparted to the under surface cf the button which is affixed in place over a pre-selected acupuncture point.
- One polarity is on the upper surface of the button (the domed surface away from the 1 _ skin) and the other pole is on the lower surface of the button in contact with the skin.
- Still another form of administering homeopathic medicaments is orally by means of a pill or tablet. Two such oral tablets are shown in Figures 1A and IB.
- this oral device can aptly be described as a medicinal "lollipop" consisting of a rod portion 40 and a ball or bulbous portion 42.
- the rod 40 is made up of a metal such as iron capable of holding a magnetic charge.
- the ball portion 42 has an inert core such as molded plastic, for example.
- the rod 40 is coated with a plastic or vinyl coating 44 extending to the ball portion 42.
- the ball portion 42 is coated with a homeopathic composition made of sugar and Ferrous gluconate mixed to a dilution in the range of 3x to 4x. It is then impregnated with an alcohol tincture containing the desired homeopathic medicament.
- the entire device can be encased in a sanitary wrapping.
- the entire device in its wrapping if desired is first placed in a suitable electromagnetic field.
- all of the metallic elements of the device are magnetized with the ball portion being charged with one polarity and the rod portion with the opposite polarity.
- the therapeutic portion of the device having a unipolar charge can then be placed under the tongue of the patient in order to contact the acupuncture points in the mouth.
- a pill as shown in Figure IB can be used.
- the pill 50 has a core 52 formed of a standard homeopathic sugar globule made in conventional manner.
- Dry Ferrous gluconate powder (USP grade) is triturated with very fine sugar in a 1-9 proportion in a grinding machine to make a homeopathic dilution of 2X.
- a second dilution (designed as 3X) is made in the same 1-9 proportions using the 2X dilution and additional sugar. Succeeding dry dilutions are made in the same manner to a final dilution of 5X.
- the 5X dilution of the Ferrous gluconate and sugar is used to build inner layer 54 which surrounds the core 52.
- Layer 54 is built up by tu bling in a coating pan in accordance with known methods for the manufacture of homeopathic remedies. Layer 54 is then covered with a coating 56 which is impermeable to water and alcohol. Ferrous gluconate is added to coating 56 so that it will have the same magnetic permeability as layer 54 containing ferrous gluconate and sugar. An outer layer 58 is then built up around coating 56 in the same manner as inner layer 54 was formed. The thickness of outer layer 58 should be approximately twice that of inner layer 5? for optimum results and is similarly made of a Ferrous gluconate sugar mixture in 5X dilution. The pills are then thoroughly air dried. The diameter of the finished pill should preferably be approximately one centimeter.
- the layered pill made a.ccording to this procedure can then be medicated in conventional manner.
- a measured weight of the finished, dried pills is placed in a suitable container and a predetermined amount of the desired homeopathic medicinal tincture is added.
- the homeopathic tincture is of a dilution of 3OX which has been manufactured ir. accordance with traditional homeopathic procedure from herbs or other raw materials.
- the containers with the pills are then rotated in a roller mill for approximately one hour to permit the pills to completely absorb the alcohol tincture.
- the pills are then transferred from the containers to paper covered trays where they are air drie ⁇ until no trace or odor of the alcohol remains.
- the pills are then individually packaged (a single pill to each container) in a vial-like tube with a threaded cap or tightly fitting friction lid.
- the cap is preferably larger in diameter than the vial so that it projects to form a rim around the vial at the top. Pre ⁇ cautions should be taken during processing to avoid contamina ⁇ tion or de-activation of th -pills.
- the medicated pills can then be administered to the patient.
- a vial containing the pills is placed into a ⁇ uit- able magnetic filed so that each piil is magnetized just pricr to inge ⁇ tion by the patient.
- the pill should be inserted directly into the mouth from the vial without handling.
- the patient can then suck on the pill to gradually dissolve it until the impermeable coating is reached at which point the patient should discard the remainder of the pill.
- Yet another form of administering the homeopathic medicaments is by auricular measures.
- One such device consists of an earplug containing dosages of the homeopathic medicament which can be administered through holes in the earplug to the acupuncture points in the ear.
- the earplug device can be made by any number of means with the understanding that it must be able to uncontrollably release medicament to predetermined auricular acupuncture points. This can best be accomplished by either using rods or small protrusions aligned with the acupuncture points and capable of releasing medicament.
- the homeopathic medicament is magnetized after it is deposited in the earplug device in accordance with the procedure described above for imparting a magnetic charge to the topical or oral forms of administration.
- An injectable dosage form of an herb-based homeopathic medicament designated FNG-11, for the treatment of fungus and yeast infections, having a homeopathic potency of SOX was prepared from an original concentrated tincture menstrum containing extracts cf the herbs Tecoma conspicua and
- Example 2 Melaleuca alternifolia in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed depending upon the number of acupuncture points being used. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above. Example 2
- the original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 X (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
- Injectable dosage portions of 0.2cc volumes were set aside as needed.
- the formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
- An injectable dosage form of an herb-based homeopathic medicament designated VR-27, for the treatment of broad spectrum viral infections, having a homeopathic potency of SOX was prepared from an original concentrated tincture menstruum containing an extract of the herb Centella asiatica minor in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency cf 4 x (10-4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions cf 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above. Example 4
- the original concentrated tincture was then diluted to 30X potency (10 ⁇ " times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed.
- An injectable dosage form of an herb-based homeopathic medicament for the treatment of hypothyroidism, was prepared from an original concentrated tincture menstruum containing an extract of the herb Organ protomcrpho im in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency of 4 x (10 -4-) , was added to the dilute homeopathic solution in order for it to hol a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
- An injectable dosage form of an herb-based homeopathic medicament for the treatment of premenstrual syndrome, menopause, and reproductive hormonal imbalance, was prepared from an original concentrated tincture menstruum containing an extract of the herb Angelica sinensis in 99+% alcohol.
- the original concentrated tincture was then diluted to 30X potency (10 times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x 10 ) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
- Injectable dosage portions of 0.2cc volumes were set aside as needed.
- Example 7 An injectable dosage form of a homeopathic medicament, designated HYT-12, for the treatment of hydro- thyroidism, was prepared from an original concentrated tincture menstruum containing a solution of aqueous iodine in
- the original concentrated tincture was diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically permeable substance in. a homeopathic potency of 4 x f!0 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
- Injectable dosage portions of 0.2cc volumes were set aside as needed.
- the formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
- Example 8 An injectable dosage form of an herb-based homeopathic medicament for the treatment of hypertension, designated RLX-22, was prepared from an original tincture menstruu containing extracts of the herbs Rock Pose, Clematis, Impatien ⁇ , Cherry Plum, and Star of Bethlehem in
- An injectable dosage form of an herb-based homeopathic medicament, designated IMM-2, for restoring and strengthening the body's natural immune system, having a homeopathic potency of 30X was prepared from an original concentrated tincture menstruum containing extracts of the herbs Astragalus membranaceous, Nux vomica, Panix ginseng, Germanium and extract of Thymus gland in 99+% alcohol. The original concentrated tincture was then diluted to 3OX potency (10 -30 times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
- Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
- An injectable cc ⁇ are form of a homeopathic medicament for the treatment of hypoglycemia designated HYG-6, was prepared from an original concentrated tincture menstruum containing sulfur and glycerin in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the ori ⁇ inal concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge w en passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed.
- Example 11 An injectable dosage form of an herb-based homeopathic medicament, designated INF-16, for the treatment of bacterial infections, particularly staff and strep, was prepared from an original concentrated tincture menstruum containing extracts of the herbs Senecia scandens, Scutellaria baicalensis, Magnolia officinalis, Lonicera japonica, and
- Andrographis paniculata in 99+% alcohol was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field.
- Injectable dosage portions cf 0.2cc volumes were set aside as needed.
- An injectable dosage form of an herb-based homeopathic medicament, designated FLU-17, for the treatment of viral infections due to colds and influenza, particularly rhino-virus, was prepared from an original concentrated tincture menstruum containing extracts of the herbs Lonicera confusa. Chrysanthemum indicum, Vitex negundo, Eucdia epta, Ilex asprella, Menthol, and Baphicacan hu ⁇ cu ⁇ ia in 99+% alcohci. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline.
- Ferrous gluconate a magnetically — A permeable substance in a homeopathic potency of 4 x (10 * ) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above.
- Ferrous gluconate a magnetically permeable substance in a homeopathic potency of 4 x (10 -4) , was added to the dilute homeopathic solution in order for it to hold a magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized at the time of administration through the acupuncture sites as described above.
- Example 14
- An injectable dosage form of an herb-based homeopathic medicament for the treatment of chronic muscular and joint pain, was prepared from an original ccncentrated tincture menstruuiri containing an extract of the herb Rhus toxicodendron in 99+% alcohol. The original concentrated tincture was then diluted to 30X potency (10 -30 times the original concentration) with sterile isotonic saline. Ferrous gluconate, a magnetically permeable substance in a homeopathic potency cf 4 (10 -4) , was added to the dilute homeopathic solution in order for it to hold ⁇ magnetic charge when passed through a magnetic field. Injectable dosage portions of 0.2cc volumes were set aside as needed. The formulations injected were controllably magnetized during administration through the acupuncture sites as described above. Example 15
- SMK-30 An injectable dosage form of ⁇ homeopathic medicament, designated SMK-30, for the treatment of nicotine addiction and the craving to smoke cigarettes, other nicotine containing tobacco products, and the like, having a homeopathic potency cf 3OX was prepared from an original
- An oral dosage form of the herb-based homeopathic medicament FNG-11, prepared as set forth in Example 1 above, 25 having a homeopathic potency of 3OX was prepared in accordance with the procedure described above in connection with the pill illustrated in Figure IB.
- Example 20 An oral dosage form of the herb-based homeopathic medicament SPN-7 , as in Example 4, having a homeopathic potency cf SOX, was prepared according to the method of Example 16.
- Example 20 An oral dosage form of the herb-based homeopathic medicament SPN-7 , as in Example 4, having a homeopathic potency cf SOX, was prepared according to the method of Example 16.
- Example 21 An oral dosage form of the homeopathic medicament TYR-10, as in Example 5, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 21 An oral dosage form of the homeopathic medicament TYR-10, as in Example 5, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 22 An oral dosage form of the herb-based homeopathic medicament HRM-4, as in Example 6, having a homeopathic pctency of 30X, was prepared according to the method of Example 16.
- Example 22 An oral dosage form of the herb-based homeopathic medicament HRM-4, as in Example 6, having a homeopathic pctency of 30X, was prepared according to the method of Example 16.
- Example 23 An oral dosage form of the herb-based homeopathic medicament RLX-22, as in Example 8, having a homeopathic pctency cf 30X, was prepared according to the method of Example 16.
- Example 24 An oral dosage form cf the herb-based homeopathic medicament IMM-2, as in Example 9, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 25 An oral dosage form cf the herb-based homeopathic medicament HYG-6, as in Example 10, having a homeopathic potency of 3OX, was prepared according to the method cf Example 16.
- Example 26 An oral dosage form cf the herb-based homeopathic medicament I1F-16, as in Example 11, havir. ⁇ ⁇ homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 27 An oral dosage form cf the herb-based homeopathic medicament I1F-16, as in Example 11, havir. ⁇ ⁇ homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 28 An oral dosage form of the herb-based homeopathic medicament GLG-17, as in Example 12, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 28
- Example 29 An oral dosage form of the herb-based homeopathic medicament ALL-5, as in Example 13, having a homeopathic potency of SOX, was prepared according to the method of Example 16.
- Example 29 An oral dosage form of the herb-based homeopathic medicament ALL-5, as in Example 13, having a homeopathic potency of SOX, was prepared according to the method of Example 16.
- Example 30 An oral dosage form of the herb-based homeopathic medicament OPN-26, as in Example 14, having a homeopathic potency of 30X, was prepared according to the method of Example 16.
- Example 30
- Example 16 where the original concentrated tincture menstruum contained extracts of the herb Coryandru ⁇ ⁇ ativa.
- Example 31 A combined treatment regimen utilizing both the injectable and oral dosage forms of the FNG-11 homeopathic medicament (prepared according to Examples 1 and 16, respectively) , was used in the treatment of a 44 year old female patient. Prior to treatment the patient exhibited symptoms including mood swings, premenstrual syndrome (P. .S.), and fatigue, and was diagnosed as a result of visible yeast in a live cell analysis as suffering from candidiasis.
- the injectable form dosage of FNG-11 was administered two times per week during the first week and once per-week thereafter bilaterally to the two SP-6 acupuncture points. Duration of treatment by the injectable mode was for a total period of four weeks.
- Oral dosage forms were admini ⁇ tered at an initial dosage rate of 3 tablets taken 5 times per day during the first week of treatment, reduced to 3 times per day during the second week of treatment and finally to 2 times per day for the balance of the duration of the treatment.
- the total duration of treatment under the oral form was for a period of 4 weeks.
- the patient's blood level yeast decreased by 60%.
- the patient's P.M.S. and other symptoms were controlled.
- Example 32 A combined treatment regimen utilizing both the injectable and oral dosage forms of the VR-27 homeopathic medicament (prepared according to Examples 3 and 18, respectively) , was used in the treatment of a 41 year old male exhibiting symptoms including a histcry cf prostatiti ⁇ and gonorrhea with active leiscn ⁇ approximately 60-70% of the time. The patient was diagnosed as being infected with herpes simplex 2.
- the injectable form dosage of the VR-27 was administered two times per week during the first week and once per week thereafter bilaterally to the two Tk-5 acupuncture points and the oral form dosage was administered initially at a rate of 3 tablets taken 5 times per day during the first week of treatment, reduced to 3 times per day during the second week of treatment and finally to 2 times per day for the balance of the duration of the treatment. Both the injectable and oral form dosages were administered for a total treatment period of 6 weeks. After 3 weeks of treatment, the patient 8 s condition improved to the extent that there were no active lesions and no further outbreaks of genital herpes.
- Example 33 A combined treatment regimen of oral and injectable forms of VR-27 was utilized in the treatment of a 33 year old female of slender build and good muscle structure.
- the patient exhibited classic symptoms of Chronic Epstein-Barr Virus including chronic fatigue, unrefreshed sleep, dark circles under the eyes, headaches, burning eyes, hypersensitivity to bright lights and smoke, non-specific muscle aches in shifting locales, lack of coordination, lack of balance, and persistent bouts of depressions that sometimes reached profound levels. She was uncertain of exact dates but felt that she had had most of these symptoms for several years.
- VGA E-B Virus antibody virus titer
- the patient was treated on a weekly basis with the homeopathic medicament by taking 3 oral tables t.i.d.
- the injectable form of VR-27 was injected through the TW-5 acu- puncture point.
- Treatment continued for a period of approxi ⁇ mately 2 months.
- the follow-up blood work shewed that the same anti-body titer had fallen to a level of 1:320; well below the critical point and within the range considered normal.
- the clinical signs and symptoms confirmed the lab work and the patient reported virtual freedom from the previous physical and emotional problems. She continued to be free of symptoms 18 months later.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN258/CAL/89A IN169075B (enrdf_load_stackoverflow) | 1988-04-01 | 1989-04-05 | |
IN1043/CAL/90A IN171749B (enrdf_load_stackoverflow) | 1988-04-01 | 1992-12-19 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US176,731 | 1980-08-11 | ||
US17673188A | 1988-04-01 | 1988-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989009049A1 true WO1989009049A1 (en) | 1989-10-05 |
Family
ID=22645606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/001400 WO1989009049A1 (en) | 1988-04-01 | 1989-04-03 | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0409893A4 (enrdf_load_stackoverflow) |
JP (1) | JPH03503648A (enrdf_load_stackoverflow) |
AU (1) | AU632481B2 (enrdf_load_stackoverflow) |
CA (1) | CA1334936C (enrdf_load_stackoverflow) |
IN (1) | IN169075B (enrdf_load_stackoverflow) |
NZ (1) | NZ228593A (enrdf_load_stackoverflow) |
WO (1) | WO1989009049A1 (enrdf_load_stackoverflow) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0469661A1 (en) * | 1990-08-01 | 1992-02-05 | Enza Ciccolo | Method for the indentification of frequency and bioenergetic activities in waters and their use |
FR2675385A1 (fr) * | 1991-04-18 | 1992-10-23 | Boulay Maurice | Produit calmant et revitalisant contenant de la poudre d'aimant. |
WO1997001355A1 (en) * | 1995-06-26 | 1997-01-16 | Antonio Sacchetti | Magnetic or electromagnetically induced energization of natural substances |
WO2002066041A1 (en) * | 2001-02-23 | 2002-08-29 | Herbal Detox Therapy Aps | Natural composition |
US6552035B2 (en) * | 2001-09-13 | 2003-04-22 | Hwa-Mok Park | Composition for inducing smoking cessation comprising alkaloids from Radix ipecauanhae |
US6844014B1 (en) | 2002-07-22 | 2005-01-18 | Stephen Rafkin | Herbal healing lotion for veterinary use |
CN106714815A (zh) * | 2014-07-11 | 2017-05-24 | M·格罗斯 | 促使吸烟者戒烟的顺势疗法药剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003712A1 (en) * | 1991-08-20 | 1993-03-04 | Daniel Mcnair | A device for the administration of homeopathic compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
JPS63159313A (ja) * | 1986-12-24 | 1988-07-02 | Olympus Optical Co Ltd | 治療用薬剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2671451A (en) * | 1952-06-16 | 1954-03-09 | Stephen J Bolger | Remedial pill |
DE1467974A1 (de) * | 1964-06-08 | 1969-01-23 | Tsukamoto Kenkichi | Verfahren zur Verbesserung der Wirksamkeit von Eisenpraeparaten und Vorrichtung zur Durchfuehrung des Verfahrens |
DE1492136A1 (de) * | 1965-01-30 | 1969-09-18 | Seuss Dr Med Willy | Einrichtung zur therapeutischen Beeinflussung des menschlichen Koerpers durch statische Elektrizitaet |
DE1692771A1 (de) * | 1968-02-24 | 1972-01-05 | Willy Dr Med Seuss | Verfahren zur Zubereitung innerlich oder aeusserlich anwendbarer physiologisch wirksamer Stoffe und danach hergestellte Mittel |
BE759692A (fr) * | 1969-12-23 | 1971-05-17 | Soliman Henri | Medicament mineralo-vegetal |
FR2258839A1 (en) * | 1974-01-28 | 1975-08-22 | Sitbon Georges | Colloidal therapeutic iron solutions - treatment for cancer, leukaemia, arterial and cardiac disorders, neurological disorders, anti-radiation agents, etc. |
SE431214B (sv) * | 1977-06-02 | 1984-01-23 | Klaus H Mosbach | Sett att framstella magnetiska polymerpartiklar som berare av en foretredesvis biologiskt aktiv substans |
US4357259A (en) * | 1977-08-01 | 1982-11-02 | Northwestern University | Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres |
JPS576041A (en) * | 1980-02-25 | 1982-01-12 | Kimikiyo Harada | Folding formation type metal stud |
FR2477022A1 (fr) * | 1980-03-03 | 1981-09-04 | Flux Yang Ste Civile | Dispositif pour l'application localisee d'un champ magnetique sur un objet, notamment un etre vivant |
JPS5945378A (ja) * | 1982-09-09 | 1984-03-14 | Toyobo Co Ltd | 粘着材料 |
JPS6032716A (ja) * | 1983-07-29 | 1985-02-19 | Yasuo Sawada | 特殊脂肪酸と磁化鉄粉含有の殺菌薬と病体の恢復力を速める薬の製造方法 |
JPS61115015A (ja) * | 1984-11-08 | 1986-06-02 | Shimazaki Shiyubiyou Kk | 帯磁化粧品 |
EP0208362A1 (en) * | 1985-06-28 | 1987-01-14 | The Procter & Gamble Company | Dietary supplements containing iron and enterically coated calcium |
JPS62175419A (ja) * | 1986-01-25 | 1987-08-01 | Tomoji Tanaka | 人工温泉浴剤 |
DE3634121A1 (de) * | 1986-05-09 | 1987-11-12 | Otto Kausch | Verfahren und einrichtung zur verbesserung der wirkungen fluessiger oder pastoeser praeparate |
-
1989
- 1989-03-31 CA CA000595327A patent/CA1334936C/en not_active Expired - Fee Related
- 1989-04-03 AU AU34260/89A patent/AU632481B2/en not_active Ceased
- 1989-04-03 WO PCT/US1989/001400 patent/WO1989009049A1/en active Application Filing
- 1989-04-03 JP JP1504757A patent/JPH03503648A/ja active Pending
- 1989-04-03 EP EP19890904967 patent/EP0409893A4/en not_active Withdrawn
- 1989-04-03 NZ NZ228593A patent/NZ228593A/en unknown
- 1989-04-05 IN IN258/CAL/89A patent/IN169075B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
JPS63159313A (ja) * | 1986-12-24 | 1988-07-02 | Olympus Optical Co Ltd | 治療用薬剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0409893A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0469661A1 (en) * | 1990-08-01 | 1992-02-05 | Enza Ciccolo | Method for the indentification of frequency and bioenergetic activities in waters and their use |
FR2675385A1 (fr) * | 1991-04-18 | 1992-10-23 | Boulay Maurice | Produit calmant et revitalisant contenant de la poudre d'aimant. |
WO1997001355A1 (en) * | 1995-06-26 | 1997-01-16 | Antonio Sacchetti | Magnetic or electromagnetically induced energization of natural substances |
WO2002066041A1 (en) * | 2001-02-23 | 2002-08-29 | Herbal Detox Therapy Aps | Natural composition |
US6552035B2 (en) * | 2001-09-13 | 2003-04-22 | Hwa-Mok Park | Composition for inducing smoking cessation comprising alkaloids from Radix ipecauanhae |
US6844014B1 (en) | 2002-07-22 | 2005-01-18 | Stephen Rafkin | Herbal healing lotion for veterinary use |
CN106714815A (zh) * | 2014-07-11 | 2017-05-24 | M·格罗斯 | 促使吸烟者戒烟的顺势疗法药剂 |
EP3166620B1 (de) * | 2014-07-11 | 2025-04-23 | Marianna Gross | Homöopathisches mittel zur raucherentwöhnung |
Also Published As
Publication number | Publication date |
---|---|
JPH03503648A (ja) | 1991-08-15 |
IN169075B (enrdf_load_stackoverflow) | 1991-08-31 |
AU632481B2 (en) | 1993-01-07 |
CA1334936C (en) | 1995-03-28 |
NZ228593A (en) | 1992-07-28 |
EP0409893A1 (en) | 1991-01-30 |
AU3426089A (en) | 1989-10-16 |
EP0409893A4 (en) | 1991-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5162037A (en) | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration | |
WO2009051628A2 (en) | Transdermal treatment device and method | |
AU723812B2 (en) | Medicinal preparation and a method of medicinal action on human organism | |
US4352796A (en) | Pharmaceutically active plant extract and composition thereof | |
CN101417013A (zh) | 一种用于风湿骨痛的中药巴布剂及其制备方法 | |
EP1162988A1 (en) | Wafer delivery system | |
AU632481B2 (en) | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration | |
TWI352597B (en) | Composition having effect of moxibustion and press | |
CN106038479B (zh) | 一种蛇床子微囊温敏凝胶及其制备方法与质量检测方法 | |
US5603935A (en) | Composition for the treatment of snoring and methods of use thereof | |
CN103495042A (zh) | 一种用于治偏头痛的中药组合物 | |
CN102552440B (zh) | 一种平喘消炎药物及其制备方法和用途 | |
CN101361868B (zh) | 一种治疗风湿的中药组合物 | |
CN102614375B (zh) | 一种补肾壮阳、治疗阳痿的中药组合物及其制备方法 | |
CN101181602B (zh) | 一种中药制剂、其制备方法及在制备抗病毒、抗菌药物中的应用 | |
WO2002094297A1 (en) | Herbal composition for the treatment of drug addiction and insomnia | |
CN1080563C (zh) | 向日葵秆芯作为制备治疗癌症的药剂的用途 | |
Biddle | Materia medica | |
CN1092976C (zh) | 苦荬菜在制备治疗结核病药物方面的用途 | |
AU2002254806B2 (en) | Herbal composition for the treatment of drug addiction and insomnia | |
CN1116106A (zh) | 治疗女性外生殖器疾患的药物制剂洁阴净 | |
CN120550017A (zh) | 一种治疗膝骨关节炎的中药组合物及其制备方法 | |
Biddle | Review of Materia Medica: For the Use of Students | |
CN103599185A (zh) | 一种用于治疗头痛的中药组合物 | |
CN112704725A (zh) | 一种中药热敷包及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR DK FI HU JP LK NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989904967 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1989904967 Country of ref document: EP |